Скачать с ютуб Insights into the BrECADD regimen in HL & results from the GHSG HD21 study в хорошем качестве

Insights into the BrECADD regimen in HL & results from the GHSG HD21 study

Patients with Hodgkin lymphoma (HL) receiving treatment with escalated BEACOPP have promising outcomes, however, there are concerns with this regimen regarding toxicities. Therefore, novel approaches are being explored, including the BrECADD regimen, which incorporates brentuximab vedotin into the BEACOPP backbone. In this video, Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, shares some insights into the efficacy of this regimen and further discusses results from an interim analysis of the GHSG HD21 study (NCT02661503). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.